Skip to main content
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. — Investor Relations & Filings

Ticker · MCRB ISIN · US81750R2013 LEI · 549300GMXBE5NUWISF13 US Manufacturing
Open in API
Filings indexed 668 across all filing types
Latest filing 2020-08-13 Capital/Financing Update
Country US United States of America
Listing US MCRB

About Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Seres Therapeutics, Inc. is a commercial-stage biotechnology company developing microbiome-based therapeutics. The company's platform creates a novel class of biological drugs, known as live biotherapeutics, which consist of rationally selected consortia of live bacteria. These therapies are designed to modulate the functional properties of the gastrointestinal microbiome to treat and prevent diseases. Seres' development programs target medically vulnerable patient populations, with a focus on preventing bacterial bloodstream and antimicrobial-resistant (AMR) infections, as well as treating gastrointestinal-related immune diseases.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) dated August 12, 2020, relating to a preliminary prospectus dated August 11, 2020, filed pursuant to Rule 433. It announces the pricing of a public offering of common stock shares by Seres Therapeutics, Inc., including details about the offering size, price, underwriters, and intended use of proceeds. The document is primarily an announcement of a capital raising event and related offering details, not a full financial report or earnings release. It does not contain financial statements or management discussion of results but focuses on the financing activity and offering terms. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief notice or regulatory filing. Confidence is high given the clear content and context.
2020-08-13 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) dated August 12, 2020, relating to a Preliminary Prospectus dated August 11, 2020, filed pursuant to Rule 433. It discusses a concurrent placement of shares, conditions related to the Hart-Scott-Rodino Antitrust Improvements Act, and references the registration statement on Form S-3. The content focuses on updating and supplementing the preliminary prospectus for a securities offering, which is a type of capital raising activity. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities. The document is about a securities offering and concurrent placement, not a full prospectus or annual report, and it is not merely an announcement of a report but a substantive update on financing terms and conditions. Therefore, the appropriate classification is CAP with high confidence.
2020-08-12 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of 8,000,000 shares of common stock by Seres Therapeutics, Inc., including underwriting details, risk factors, use of proceeds, and other offering-related information. The document is not a financial report, earnings release, or management discussion, but rather a capital raising disclosure document. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is the actual prospectus supplement, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2020-08-11 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 registration statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933, used for registering securities to be offered to the public. The text includes details about the securities being registered, the registration fee, and the prospectus for the offering. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities issuance. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2020-08-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 10, 2020, by Seres Therapeutics, Inc. It includes disclosures about an updated corporate slide presentation (Exhibit 99.1) and a press release (Exhibit 99.2) announcing positive topline results from a Phase 3 clinical study. The document does not contain detailed financial statements or comprehensive financial analysis but rather regulatory disclosures and event announcements. The presence of a corporate slide presentation and a press release attached as exhibits, and the nature of the content focusing on clinical trial results and regulatory updates, indicate this is a regulatory filing reporting material events rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-08-10 English
10-Q
Interim / Quarterly Report Q2 2020
2020-07-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.